Efficacy of rechallenge with BRAF inhibition therapy in patients with advanced BRAFV600 mutant melanoma
暂无分享,去创建一个
[1] Veerendra Koppolu,et al. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma , 2018, Journal of cancer research and therapeutics.
[2] J. Utikal,et al. The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study , 2018, Oncotarget.
[3] D. Schadendorf,et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. , 2018, The Lancet. Oncology.
[4] M. Weichenthal,et al. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. , 2018, European journal of cancer.
[5] É. Drumez,et al. BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response , 2017, Melanoma research.
[6] R. Dummer,et al. Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600‐mutated melanoma , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.
[7] Bart Neyns,et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. , 2017, The Lancet. Oncology.
[8] P. Wolter,et al. Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination , 2017, Melanoma research.
[9] F. Cappuzzo,et al. Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. , 2016, Lung cancer.
[10] K. Flaherty,et al. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy , 2016, Cancer cell.
[11] C. Lebbé,et al. BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma , 2015, Melanoma research.
[12] J. Mackiewicz,et al. Resistance to Vemurafenib Can Be Reversible After Treatment Interruption , 2014, Medicine.
[13] P. Ascierto,et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.
[14] R. Bernards,et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.
[15] S. Pradervand,et al. Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression , 2013, Clinical Cancer Research.
[16] K. Flaherty,et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] W. Sellers,et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance , 2013, Nature.
[18] B. Neyns,et al. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. , 2012, Melanoma research.
[19] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[20] Y. Hatanaka,et al. Sorafenib rechallenge in patients with metastatic renal cell carcinoma , 2012, BJU international.
[21] J. Blay,et al. Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib , 2012, Annals of Surgical Oncology.
[22] T. Choueiri,et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients , 2010, Cancer.
[23] A. Hauschild,et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. Weichenthal,et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] D. Schadendorf,et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.